SEC Filings
Ardelyx Faces A New Securities Class Action Reaching Back To January 2025
A September suit and an October derivative case target the drugmaker, which says it cannot estimate any loss.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
A September suit and an October derivative case target the drugmaker, which says it cannot estimate any loss.
SEC Filings
Vertex's preliminary accounting puts $5,116.0 million on atumelnant, a Phase 3 drug, against $1,335.4 million of goodwill.
SEC Filings
Voyager booked a $53.9 million loss provision on the lunar business's contracts as fixed-price work swelled and gross margin fell to 11.5%.
Deals
The lymphoma-drug maker says holders keep the same share count and its NYSE listing, but Swiss tax rulings must come first.
Deals
The insurer's quarterly report also shows a 50 million-share buyback add-on and a $1.5 billion acquisition bill still owed.
SEC Filings
The Argentine lender paid an average Ps$ 9,840.412 a share, according to a notice to the country's securities regulator.
Deals
Two auditor sign-offs were the only new exhibits in an amended registration covering 7.087% and 7.337% senior secured notes.
SEC Filings
A convertible note sale, a term loan payoff and heavy repurchases left Tenable with a $26.5 million stockholders' deficit.
SEC Filings
A $668.3 million quarterly loss hit the eye-drug maker's balance sheet, and its cash runway assumes no milestone payments come due.
Earnings
Revenue rose 2.8% to $488.7 million, but anniversary stock awards for nearly all employees pushed the casino operator into a quarterly loss.
Earnings
Revenue rose 15.0% to $154.5 million in the third quarter, and the company lifted its full-year revenue outlook.
Earnings
Adjusted EBITDA rose 39.2% to $79.5 million, but a $39.2 million non-cash tax benefit swelled net income to $74.5 million.